Table 3 The cumulative incidence of common adverse events in SGLT2i and RAAS blockade users.

From: Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease

Side effects

SGLT2i users

(n = 1,405)

RAAS blockade users

(n = 5,541)

RR (95% CI)

P-value

Urinary tract infections, n (%)

67 (4.77)

364 (6.57)

0.73 (0.56–0.94)

0.013*

Acute kidney injury, n (%)

79 (5.82)

348 (6.28)

0.90 (0.71–1.13)

0.361

Bone fractures, n (%)

21 (1.49)

121 (2.18)

0.68 (0.43–1.08)

0.106

Fournier gangrene, n (%)

4 (0.28)

8 (0.14)

1.97 (0.59–6.54)

0.267

Hypoglycemia, n (%)

9 (0.64)

19 (0.34)

1.87 (0.85–4.12)

0.121

Diabetic ketoacidosis, n (%)

3 (0.21)

3 (0.05)

3.94 (0.80–19.52)

0.093

Hypotension, n (%)

8 (0.57)

21 (0.38)

1.50 (0.67–3.38)

0.326

Limb amputation, n (%)

8 (0.57)

20 (0.36)

1.58 (0.70–3.57)

0.275

  1. *P−value < 0.05.
  2. Abbreviations: CI, confidence interval; RAAS blockade, renin−angiotensin−aldosterone blockade; RR, risk ratio; SGLT2i, sodium−glucose cotransporter−2 inhibitors.
Back to article page